원발성 경화성 담관염에서의 대변 미생물 이식 (FARGO)
FARGO: 원발성 경화성 담관염에 대한 FAecal 미생물군 이식에 대한 무작위, 제2a상, 다기관, 위약 대조 시험
FARGO is a randomised, phase IIa, multi-centre, placebo-controlled trial to compare Faecal Microbiota Transplant (FMT) with placebo in patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Primary Sclerosing Cholangitis (PSC) is a chronic liver disease and there is no medical therapy proven to slow disease progression. Many patients with PSC also develop inflammatory bowel disease (IBD). It has been shown that there is an imbalance of 'normal' microbiome (e.g. bacteria, viruses, fungi) in the gut of people with PSC and IBD. This imbalance is believed to contribute to the development (and possibly worsening) of liver disease in PSC.
It is believed that Faecal Microbiota Transplant (FMT) treatment can restore the balance in the gut microbiome and that this can lead to reduction in symptoms of PSC and IBD and improve quality of life.
FMT involves the transplantation of faeces (or stool) from a healthy individual to a person with PSC. FMT is prepared from stool collected from unrelated, anonymous, healthy donors. The stool is treated in a laboratory at the University of Birmingham. The donors are carefully screened and the donated stool carefully tested to ensure that it is as clean and safe as possible before it is made into doses of FMT suitable for treatment purposes. Data from treatment with FMT in other conditions including Inflammatory Bowel Disease (IBD), Clostridioides difficile (C.diff) infection and PSC has shown FMT to be safe.
The primary aim of the FARGO trial is to determine the efficacy of FMT in patients with PSC. The FARGO trial will recruit 58 patients. Half will be randomised to FMT and half to placebo. The trial will be offered at a number of hospitals across England. Patients will be involved in the trial for 50 weeks, including a 2-week screening, 8 treatments over 8 weeks, and follow-up to 48 weeks post-randomisation. Trial visits will include the collection of health history, blood tests, stool tests, pregnancy tests (if applicable), medication reviews, disease specific measures, patient questionnaires and possible symptom and side-effect review. Research blood, urine, stool and colonic biopsy samples will also be collected.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Anna Rowe
- 전화번호: +44 (0121) 3718117
- 이메일: FARGO@trials.bham.ac.uk
연구 연락처 백업
- 이름: Helen Coulthard
- 전화번호: +44 (0121) 3718198
- 이메일: FARGO@trials.bham.ac.uk
연구 장소
-
-
-
Birmingham, 영국, B15 2TH
- 모병
- Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
-
수석 연구원:
- Palak Trivedi
-
London, 영국, NW3 2QG
- 모병
- Royal Free Hospital, Royal Free London NHS Foundation Trust
-
수석 연구원:
- Douglas Thorburn
-
London, 영국, SE5 9RS
- 모병
- King's College Hospital, King's College Hospital NHS Foundation Trust
-
수석 연구원:
- Deepak Joshi
-
London, 영국, NW10 7NS
- 모병
- St Mark's Hospital, London North West University Healthcare NHS Trust
-
수석 연구원:
- Ailsa Hart
-
Oxford, 영국, OX3 9DU
- 모병
- John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust
-
수석 연구원:
- Emma Culver
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Written informed consent
-
Age ≥ 18 years
-
Participants must be able to understand and comply with the purpose and procedures that are involved in the trial
-
An established diagnosis of colonic inflammatory bowel disease, with willingness to participate in an annual colonoscopic surveillance program, as per routine standard of care
-
An established clinical diagnosis of large duct PSC, with compatible features as assessed by magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP)
-
A persistent ALP value above normal (at least 2 readings at this value over 6 months before screening)
-
Evidence of early to moderate stage liver fibrosis, as suspected by any of the following:
- Median VCTE score of ≤14.4kPa, with an interquartile range ≤30%
- Previous liver biopsy indicating at an absence of established cirrhosis, Ishak fibrosis stage <IV (or equivalent) in the last 24 months
- Serum enhanced liver fibrosis score (ELF) ≤9.8
-
A colonoscopy showing no evidence of dysplasia/neoplasia within 24 months before screening
-
No evidence of active colitis, as evidenced by a Partial Mayo Score of ≤4, with a score of <2 on the rectal bleeding domain at screening
-
Individuals with IBD who are receiving treatment with biologics, immunosuppression or corticosteroids must be taking a stable dose for at least twelve weeks prior to screening, and be expected to remain on the same medication/same dose for the duration of the trial
-
Individuals with PSC having overlapping features of autoimmune hepatitis may be included, provided:
- The dosage of immunosuppression has remained stable for at least twelve weeks prior to screening, and be expected to remain on the same medication/same dose for the duration of the trial; and
- There is evidence of concomitant colitis
Exclusion Criteria:
-
Secondary causes of sclerosing cholangitis including, but not limited to, IgG4-related cholangitis, cholangiopathy due to acquired immunodeficiency syndrome, drug-induced sclerosing cholangitis, trauma, ischaemic cholangiopathy, choledocholithiasis (investigator discretion), or sclerosing cholangiopathy as a sequelae of hepatopancreatobiliary resection
-
Other causes of liver disease, including, but not limited to, IgG4-related disease; viral hepatitis; alcohol-related liver disease; clinically significant metabolic associated fatty liver disease (at investigator discretion); drug-induced liver disease; hereditary haemochromatosis; alpha-1-antitrypsin disease; primary biliary cholangitis; Wilson disease; Budd-Chiari Syndrome; or primary or secondary hepatopancreatobiliary cancer
-
Presence of a clinically significant dominant stricture based on the combination of radiological, biochemical and clinical features. Patients can be included in the trial with a dominant extrahepatic stenosis if it has been stable for 6 months or more (as evidenced on imaging and also clinically), and one of the following are satisfied:
- The PI does not plan for any biliary intervention (endoscopic, percutaneous or surgical) for the duration of the trial OR
- The investigator decides that they do not wish to perform any biliary intervention (endoscopic, percutaneous or surgical) on the dominant stenosis for clinical reasons of stability/patient choice
-
Presence of a percutaneous drain or bile duct stent
-
Evidence of hepatic decompensation within twelve weeks prior to screening; or concern by the Principal Investigator that the participant may decompensate during the trial period. Hepatic decompensation as evidenced by variceal haemorrhage, ascites, hepatic hydrothorax, or hepatic encephalopathy (Appendix 1)
-
Biochemical/laboratory evidence of very advanced hepatic dysfunction, as evidenced by a serum bilirubin value >55 µmol/L (unless Gilbert Syndrome or another condition associated with unconjugated hyperbilirubinaemia, including but not limited to, spherocytosis and disorders of bilirubin conjugation where a bilirubin value>45 µmol/L is allowable), serum albumin <32 g/L, platelet level of <140x109/L, Child-Turcotte-Pugh (CTP) score >B7, or a MELD score >15
-
Ascending cholangitis as assessed clinically within twelve weeks of screening
-
Use of antibiotics within twelve weeks of screening
-
Participant already listed for liver transplantation, or concerns (investigator discretion) that they may need to be listed for liver transplantation during the trial period
-
Small duct PSC
-
Advanced-stage liver fibrosis, as evidenced by a VCTE score >14.4kPa, a liver biopsy showing >Ishak stage III fibrosis (or equivalent)
-
Significant renal dysfunction as evidenced by an estimated glomerular filtration rate of <60 ml/min according to the Cockcroft-Gault formula, or need for dialysis
-
Human Immunodeficiency Virus (HIV) infection
-
A symptomatic positive test result for Serious Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the four weeks prior to screening
-
History of malignancy within the past three years, or ongoing malignancy, other than non-melanomatous skin cancer, or treated cervical carcinoma in situ
-
Any history of small bowel or colonic resection, or likelihood of resection during the trial period. Individuals with a sub-total colectomy and ileal pouch anal anastomosis are permitted to participate.
-
Patients who are pregnant or breastfeeding
-
Women of childbearing potential (see Appendix 2 for definition) who confirm they are not willing to practise effective contraception (see Appendix 3 for further details) for the duration of the trial and for four weeks after the last dose of trial drug. Women who are taking hormonal contraception must confirm stable formulation and dosage for at least 6 weeks prior to treatment
-
Alcohol consumption >21 units per week for men, and >14 units per week for women.
-
Positive urine drug screen at screening
-
Positive stool test for Clostridioides Difficile toxin or microscopy/culture positivity for enteric infection within twelve weeks prior to screening
-
Participation in an interventional trial, or use of a non-licensed investigational agent for any indication within twelve weeks before screening, or five half-lives of the investigational drug, whichever is longer
-
Newly introduced or a change in dosage of any of the following medications within twelve weeks of screening: fibric acid derivatives, farnesoid X-receptor agonists, anti-gastrointestinal motility agents (e.g., loperamide or opioids), bile acid sequestrants (e.g. colestyramine) or ursodeoxycholic acid (UDCA)
-
Use of any of the following medications within twelve weeks of screening: oral or intravenous antibiotics, including (but not limited to) vancomycin, rifaximin, rifampicin and metronidazole; probiotic or prebiotic preparations, including (but not limited to) VSL#3 and Symprove
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Faecal Microbiota Transplant (FMT)
FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline |
FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline |
|
위약 비교기: FMT Placebo
FMT Placebo is 50mL aliquots of 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v. |
FMT Placebo is 50mL aliquots containing 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v. FMT Placebo for administration via colonoscopy will be made up of 250mL (5 aliquots). FMT Placebo for administration via enema will be made up of 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Serum Alkaline Phosphatase (ALP)
기간: ALP at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
Reduction in serum ALP values from baseline, measured at 48 weeks following the first dose of FMT or FMT Placebo. |
ALP at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Patient-reported outcome (PRO) measures
기간: PSC-PRO at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
Patient-reported outcome (PRO) measure: Primary Sclerosing Cholangitis -Patient Reported Outcome (PSC-PRO) Questionnaire |
PSC-PRO at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Patient-reported outcome (PRO) measures
기간: SF-36 at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
Patient-reported outcome (PRO) measure: short-form (SF)-36 Questionnaire |
SF-36 at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Patient-reported outcome (PRO) measures
기간: 5D-Itch at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
Patient-reported outcome (PRO) measures: 5 dimensional itch scale (5D itch) Questionnaire |
5D-Itch at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Patient-reported outcome (PRO) measures
기간: SIBDQ at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
Patient-reported outcome (PRO) measures: Short Inflammatory Bowel Disease Questionnaire (SIBDQ) |
SIBDQ at Screening (Week -2), Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Surrogate biomarkers of liver fibrosis
기간: Surrogate biomarkers of liver fibrosis: VCTE at Screening (Week -2) and Week 48
|
Surrogate biomarkers of liver fibrosis: vibration-controlled transient elastography (VCTE) |
Surrogate biomarkers of liver fibrosis: VCTE at Screening (Week -2) and Week 48
|
|
Surrogate biomarkers of liver fibrosis
기간: Surrogate biomarkers of liver fibrosis: ELF at Week 1, Week 5, Week 12, and Week 48
|
Surrogate biomarkers of liver fibrosis: enhanced liver fibrosis score (ELF) |
Surrogate biomarkers of liver fibrosis: ELF at Week 1, Week 5, Week 12, and Week 48
|
|
Routine liver laboratory parameters
기간: Routine liver laboratory parameters: ALT at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
Routine liver laboratory parameters: serum alanine transaminase (ALT) |
Routine liver laboratory parameters: ALT at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Routine liver laboratory parameters
기간: Routine liver laboratory parameters: AST at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
Routine liver laboratory parameters: serum aspartate aminotransferase (AST) |
Routine liver laboratory parameters: AST at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Routine liver laboratory parameters
기간: Routine liver laboratory parameters: bilirubin at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
Routine liver laboratory parameters: bilirubin |
Routine liver laboratory parameters: bilirubin at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Routine liver laboratory parameters
기간: Routine liver laboratory parameters: gamma glutamyl transferase at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
Routine liver laboratory parameters: gamma glutamyl transferase |
Routine liver laboratory parameters: gamma glutamyl transferase at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Routine liver laboratory parameters
기간: Routine liver laboratory parameters: albumin at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
Routine liver laboratory parameters: albumin |
Routine liver laboratory parameters: albumin at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
PSC specific prognostic scores
기간: PSC specific prognostic scores: UK-PSC Score at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
PSC specific prognostic scores: the UK-PSC Score |
PSC specific prognostic scores: UK-PSC Score at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
PSC specific prognostic scores
기간: PSC specific prognostic scores: Amsterdam-Oxford PSC Score at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
PSC specific prognostic scores: the Amsterdam-Oxford PSC score |
PSC specific prognostic scores: Amsterdam-Oxford PSC Score at Screening (Week -2), Week 1, Week 3, Week 5, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Quantitative assessment of Inflammatory Bowel Disease (IBD) activity
기간: Quantitative assessment of IBD activity: Mayo colitis score at Week 1, Week 12 and Week 48
|
Quantitative assessment of IBD activity: The Mayo colitis score |
Quantitative assessment of IBD activity: Mayo colitis score at Week 1, Week 12 and Week 48
|
|
Quantitative assessment of IBD activity
기간: Quantitative assessment of IBD activity: SES-CD at Week 1, Week 12 and Week 48
|
Quantitative assessment of IBD activity: The Simple Endoscopic Score for Crohn's Disease (SES-CD); |
Quantitative assessment of IBD activity: SES-CD at Week 1, Week 12 and Week 48
|
|
Quantitative assessment of IBD activity
기간: Quantitative assessment of IBD activity: faecal calprotectin at Screening (Week -2), Week 1, Week 5, Week 12 and Week 48
|
Quantitative assessment of IBD activity: faecal calprotectin |
Quantitative assessment of IBD activity: faecal calprotectin at Screening (Week -2), Week 1, Week 5, Week 12 and Week 48
|
|
The incidence of clinical non-trial endpoint events
기간: The incidence of clinical non-trial endpoint events at Screening (Week -2), Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 12, Week 24, Week 36 and Week 48
|
The incidence of clinical non-trial endpoint events: acute cholangitis flares (including those that are resistant to single course antibiotic treatment), acute colitis flares, and episodes/time to hepatic decompensation |
The incidence of clinical non-trial endpoint events at Screening (Week -2), Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
The incidence of trial endpoint events
기간: The incidence of trial endpoint events at Screening (Week -2), Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 12, Week 24, Week 36 and Week 48
|
The incidence of trial endpoint events: cholangiocarcinoma / hepatopancreatobiliary malignancy, referral for liver transplantation, colonic resection or colorectal cancer, and/or mortality |
The incidence of trial endpoint events at Screening (Week -2), Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 12, Week 24, Week 36 and Week 48
|
|
Occurrence of adverse events
기간: Occurrence of adverse events at Screening (Week -2), Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 12, Week 24, Week 36 and Week 48
|
Occurrence of adverse events as measured by CTCAE v5.0 |
Occurrence of adverse events at Screening (Week -2), Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 12, Week 24, Week 36 and Week 48
|
공동 작업자 및 조사자
협력자
협력자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- RG_22-063
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Anonymised patient level data may be shared in accordance with the Cancer Research UK Clinical Trials Unit (CRCTU) Data Sharing Policy. More detailed information on the CRCTU's Data Sharing Policy and the mechanism for obtaining data can be found on the CRCTU website:
https://www.birmingham.ac.uk/research/crctu/data-sharing-policy
IPD 공유 지원 정보 유형
- 연구_프로토콜
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .